Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial

STRIVE Investigators

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


Objective: To report and discuss the multi-domain impact of elosulfase alfa, with focus on tertiary and composite endpoints, in the 24-week, randomized, double-blind, placebo-controlled phase 3 trial in patients with Morquio A syndrome (mucopolysaccharidosis IVA). Methods: Patients with Morquio A syndrome aged ≥. 5. years were randomized 1:1:1 to elosulfase alfa 2.0. mg/kg/week (qw; N. = 58), elosulfase alfa 2.0. mg/kg/every other week (qow; N. = 59), or placebo (N. = 59) for 24. weeks. Primary and secondary efficacy measures were 6-minute walk test (6MWT; primary), 3-minute stair climb test (3-MSCT) and urinary keratan sulfate (KS). Safety was also evaluated. Tertiary efficacy measures included respiratory function measures, activities of daily living (MPS Health Assessment Questionnaire [MPS-HAQ]), anthropometric, echocardiographic and radiographic measures, hearing and corneal clouding assessment. In order to fully characterize treatment impact in this heterogeneous disorder, the effect of elosulfase alfa on composite efficacy measures was evaluated as well. Results: The study was not designed to have sufficient power for any of the tertiary outcomes. For most tertiary endpoints, subjects treated with the weekly dose of elosulfase alfa improved more than those receiving placebo. The largest treatment effects were seen in maximal voluntary ventilation (MVV), MPS-HAQ, height, and growth rate. The qow group appeared similar to placebo. The analysis of a pre-specified composite endpoint (combining changes from baseline in 6MWT, 3MSCT and MVV z-scores equally weighted) showed a modest positive impact of elosulfase alfa qw versus placebo group (P= 0.053). As a pre-specified supportive analysis, the O'Brien Rank Sum composite endpoint (changes from baseline in 6MWT, 3MSC, and MVV), analysis also showed that the qw group performed better than the placebo group (P= 0.011). In post-hoc analyses, combinations of other endpoints were also explored using the O'Brien Rank Sum test and showed statistically significant differences between elosulfase alfa qw and placebo favoring elosulfase alfa qw. Differences between elosulfase alfa qow and placebo were not statistically significant. Positive changes were observed in most tertiary variables, demonstrating the efficacy of weekly treatment with elosulfase alfa. Conclusions: Treatment with weekly elosulfase alfa led to improvements across most efficacy measures, resulting in clinically meaningful benefits in a heterogeneous study population.

Original languageEnglish (US)
Pages (from-to)178-185
Number of pages8
JournalMolecular Genetics and Metabolism
Issue number2
StatePublished - Feb 1 2015


  • Elosulfase alfa
  • Enzyme replacement therapy
  • Lysosomal storage disorder
  • Morquio A syndrome
  • Mucopolysaccharidosis IVA
  • Randomized controlled trial

ASJC Scopus subject areas

  • Genetics
  • Endocrinology
  • Molecular Biology
  • Biochemistry
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial'. Together they form a unique fingerprint.

Cite this